Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1390 + Radiation Therapy in Glioblastoma and Brain Metastases
NCT03423628Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2018
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of azd1390 in glioblastoma multiforme (GBM) and brain metastases (3 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of dose-limiting toxicities at 10 weeks and Incidence of adverse events and serious adverse events at 9 months. Started Apr 2018; status: completed.
02
Drugs
azd1390
03
Conditions
glioblastoma multiforme (GBM)brain metastases
Beyond the preview
Go deeper on NCT03423628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03423628.